We have previously shown that genetic deletion of Vav3, but not Vav1 and Vav2, delays BCR-ABL-induced lymphoblastic leukemia and increases the therapeutic vulnerability during TKI treatments30. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.